Canada · Delayed Price · Currency is CAD Cascades Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 results surpassed expectations with strong sequential growth in both packaging and tissue, driven by higher volumes, improved execution, and successful price increases. Outlook remains positive, with EBITDA run rate expected to exceed CAD 600 million in H2, despite cost inflation and new U.S. tariffs.
-
Q1 2026 results were impacted by weather, geopolitical events, and cost pressures, but operational improvements and asset sales supported financial stability. Guidance anticipates margin pressure in Q2, with stronger performance and a CAD 600 million EBITDA run rate targeted for the second half.
Fiscal Year 2025
-
Q4 2025 results met expectations with improved margins and strong cash flow, despite softer volumes and operational challenges in tissue. Debt reduction and asset sales progressed ahead of schedule, with 2026 EBITDA targeted above CAD 600 million.
-
Q3 results exceeded expectations with strong EBITDA growth, improved margins, and robust cash flow, driven by higher volumes and lower costs. Debt reduction and asset monetization remain priorities, while cautious Q4 guidance reflects economic uncertainty and seasonality.
-
Second quarter sales and EBITDA grew both sequentially and year-over-year, led by strong packaging performance and operational improvements. Profitability initiatives are on track, with Bear Island nearing full ramp-up and asset monetization ahead of schedule.
-
The meeting covered director elections, auditor appointment, and executive compensation, with all board recommendations approved. Financial results showed modest sales growth but lower profitability and higher debt, while strategic plans focus on efficiency, debt reduction, and sustainability. Shareholder proposals on meeting format and language disclosure were rejected.
-
Q1 2025 saw lower sequential sales and EBITDA due to trade uncertainty and softer demand, but year-over-year results improved on stronger packaging pricing. Net debt rose with higher inventories, while guidance remains cautious amid ongoing macro risks.
Fiscal Year 2024
-
Q4 2024 saw stable sequential sales and a 6% year-over-year increase, with EBITDA up 20% year-over-year. Uncertainty from potential tariffs and macroeconomic risks led to a pause in near-term guidance, while strategic priorities focus on operational excellence and debt reduction.
-
Q3 saw sequential sales and EBITDA growth, but year-over-year declines due to higher raw material costs and lower volumes. The Bear Island mill ramp-up lags targets but is improving, and the company is reorganizing for operational synergies. Leverage rose slightly as net debt fell.
-
Q2 sales rose 6% sequentially, with EBITDA up 9% from Q1 but down 20% year-over-year due to higher raw material costs. Leverage increased to 4.2x, and capital investments will be below forecast, with debt reduction prioritized. Bear Island ramp-up and new U.S. tissue business support a positive outlook.